Timothy Kyin is a Rheumatology/Immunology physician. OpenAlex indexes 15 publications with 702 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2955 Ivy Rd
Ste 311
Charlottesville, VA 229039353
Telephone
434-924-2227Provider last certified this registry record 10 Aug 2023.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARS Pharmaceuticals Operations, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- GENZYME CORPORATIONProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
82.2%Leukotriene Receptor Antagonist33.4%Montelukast Sodium100%Part D≥37 patientsCorticosteroid22.9%Budesonide-Formoterol Fumarate44%Fluticasone Propionate30%Breo Ellipta26%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
9.9%Corticosteroid9.9%Prednisone100%Part D≥22 patientsDermatology
4%Interleukin-4 Receptor alpha Antagonist4%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CysLT1R antagonists block early P2Y6 receptor-dependent signaling that prevents type 2 allergic sensitization
Journal of Allergy and Clinical Immunology
2021 - Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
The Journal of Allergy and Clinical Immunology In Practice
2020 - M563 A CASE OF ATYPICAL FOOD ALLERGY SUGGESTIVE OF SYSTEMIC CONTACT DERMATITIS
Annals of Allergy Asthma & Immunology
2020 - Alveolar macrophage P2Y6 receptors counterbalance leukotriene-dependent type 2 lung immunopathology priming function
Journal of Allergy and Clinical Immunology
2020 - P2Y6 signaling in alveolar macrophages prevents leukotriene-dependent type 2 allergic lung inflammation
Journal of Clinical Investigation
2019
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”